Mesoblast plans to file a BLA for Revascor by year-end after aligning with FDA on trial design, potency assays, and ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of ...

Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall ...

Mesoblast's RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation in the European Union (EU) ...

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and ...

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

Two biomarker tests -- one for blood and the other for stool -- are mainstays in the treatment of inflammatory bowel disease ...